Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences

DUBLIN, Ireland and TREVOSE, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, is scheduled to present a corporate overview at two upcoming investor conferences. The details are as follows: 

H.C. Wainwright 20th Annual Global Investment Conference

Date: Wednesday, September 5, 2018

Time: 12:05 p.m. ET

Location: St. Regis Hotel, New York, NY

2018 Wells Fargo Healthcare Conference

Date: Thursday, September 6, 2018

Time: 3:05 p.m. ET

Location: Westin Copley Place, Boston, MA

Both presentations will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at .

About Strongbridge Biopharma

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes MACRILEN™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency, RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. MACRILEN has orphan drug exclusivity in the United States, and both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Corporate and Media Relations

Elixir Health Public Relations

Lindsay Rocco

Investor Relations

U.S.:

Solebury Trout

Marcy Nanus

Europe:

First House

Geir Arne Drangeid







Strongbridge Biopharma plc

900 Northbrook Drive

Suite 200

Trevose, PA 19053

Tel.

Fax.